본문 바로가기

QMAC-DST for Rapid Detection of Drug Resistance in Pulmonary Tuberculosis Patients: A Multicenter Pre-Post Comparative Study

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
JOURNAL OF CLINICAL MEDICINE13(10) · 2024
피인용
Web of Science 0Scopus 0
FWCI (Scopus)
0
JCR IF
JCR 2023 3
ISSN
2077-0383

저자

  1. Kwak, Nakwon제1저자Seoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 03080, South Korea
  2. Lee, SangyeopQuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
  3. Kim, SuyeounQuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
  4. Song, EunbeeQuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
  5. Yim, Jae-JoonSeoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 03080, South Korea
  6. Shim, Tae SunUniv Ulsan, Asan Med Ctr, Coll Med, Dept Pulm & Crit Care Med, Seoul 05505, South Korea
  7. 전두수Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Yangsan 50612, South Korea
  8. Jhun, Byung WooSungkyunkwan Univ, Samsung Med Ctr, Dept Med,Sch Med, Div Pulm & Crit Care Med, Seoul 06351, South Korea
  9. Seok, Kwang-HyukKorean Inst TB, Dept Lab Med, Cheongju 28158, South Korea
  10. 김새롬Pusan Natl Univ Hosp, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
  11. Kwon, Sunghoon교신저자QuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
  12. 목정하교신저자Pusan Natl Univ, Sch Med, Dept Internal Med, Busan 49241, South Korea

초록

Background/Objectives: This study explores the impact of QMAC-DST, a rapid, fully automated phenotypic drug susceptibility test (pDST), on the treatment of tuberculosis (TB) patients. Methods: This pre–post comparative study, respectively, included pulmonary TB patients who began TB treatment between 1 December 2020 and 31 October 2021 (pre-period; pDST using the Löwenstein–Jensen (LJ) DST (M-kit DST)) and between 1 November 2021 and 30 September 2022 (post-period; pDST using the QMAC-DST) in five university-affiliated tertiary care hospitals in South Korea. We compared the turnaround times (TATs) of pDSTs and the time to appropriate treatment for patients whose anti-TB drugs were changed based on these tests between the groups. All patients were permitted to use molecular DSTs (mDSTs). Results: A total of 182 patients (135 in the M-kit DST group and 47 in the QMAC-DST group) were included. The median TAT was 36 days for M-kit DST (interquartile range (IQR), 30–39) and 12 days for QMAC-DST (IQR, 9–15), with the latter being significantly shorter (p < 0.001). Of the total patients, 10 (5.5%) changed their anti-TB drugs based on the mDST or pDST results after initiating TB treatment (8 in the M-kit DST group and 2 in the QMAC-DST group). In the M-kit DST group, three (37.5%) patients changed anti-TB drugs based on the pDST results. In the QMAC-DST group, all changes were due to mDST results; therefore, calculating the time to appropriate treatment for patients whose anti-TB drugs were changed based on pDST results was not feasible. In the QMAC-DST group, 46.8% of patients underwent the first-line line probe assay compared to 100.0% in the M-kit DST group (p < 0.001), indicating that rapid QMAC-DST results provide quicker assurance of the ongoing treatment by confirming susceptibility to the current anti-TB drugs. Conclusions: QMAC-DST delivers pDST results more rapidly than LJ-DST, ensuring faster confirmation for the current treatment regimen.

키워드

drug susceptibility testQMAC-DSTresistancetuberculosisMYCOBACTERIUM-TUBERCULOSISDIAGNOSIS

식별자

Scopus EID
2-s2.0-85194237902
WoS UID
001234862600001